CVS Health Corp (CVS.N)

CVS.N on New York Stock Exchange

101.58USD
4:01pm EDT
Change (% chg)

$0.70 (+0.69%)
Prev Close
$100.88
Open
$100.94
Day's High
$101.85
Day's Low
$100.77
Volume
1,165,572
Avg. Vol
1,349,941
52-wk High
$105.45
52-wk Low
$72.45

CVS.N

Chart for CVS.N

About

CVS Health Corporation, formerly CVS Caremark Corporation, is a pharmacy healthcare provider in the United States. The Company has three business segments: Pharmacy Services, Retail Pharmacy and Corporate. Pharmacy Services provides pharmacy benefit management (PBM) services, including plan design and administration, formulary... (more)

Overall

Beta: 1.04
Market Cap(Mil.): $114,525.70
Shares Outstanding(Mil.): 1,135.27
Dividend: 0.35
Yield (%): 1.39

Financials

  CVS.N Industry Sector
P/E (TTM): 25.39 28.59 41.92
EPS (TTM): 3.97 -- --
ROI: 8.35 10.20 72.32
ROE: 12.24 11.42 83.48
Search Stocks

Exclusive: CVS says biotech drug copies may bring price cuts of 40-50 percent

WASHINGTON - The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health Corp told Reuters.

11 Mar 2015

UPDATE 1-Samsung buys startup LoopPay, moves toward mobile payments

Feb 18 - Samsung Electronics Co Ltd has bought U.S. mobile wallet startup LoopPay, signalling its intention to launch a smartphone payments service to compete with a recent offering from rival Apple Inc.

18 Feb 2015

CVS urges cost controls for new cholesterol drugs

- CVS Health warned on Tuesday that the costs of a potent new class of cholesterol treatments could eclipse those of other expensive medicines and overwhelm the U.S. healthcare system "if rigid cost control mechanisms are not put in place."

17 Feb 2015

UPDATE 2-CVS urges cost controls for new cholesterol drugs

Feb 17 - CVS Health warned on Tuesday that the costs of a potent new class of cholesterol treatments could eclipse those of other expensive medicines and overwhelm the U.S. healthcare system "if rigid cost control mechanisms are not put in place."

17 Feb 2015

CORRECTED-UPDATE 1-CVS urges cost controls for new cholesterol, specialty drugs

Feb 17 - CVS Health on Tuesday warned that costs of a potent new class of cholesterol treatments and other specialty drugs in development could eclipse those of expensive new medicines and overwhelm the healthcare system "if rigid cost control mechanisms are not put in place."

17 Feb 2015

CVS says new cholesterol drugs could cost U.S. $150 bln/year

Feb 17 - CVS Health Corp, the second-largest U.S. pharmacy chain operator, has warned that a new class of drugs being developed to lower "bad" cholesterol could cost the U.S. healthcare system as much as $150 billion per year.

17 Feb 2015

CVS Health revenue beats as pharmacy services sales rise

- CVS Health Corp reported a better-than-expected quarterly net revenue, boosted by growth in its Medicaid business and strength in specialty drug sales.

10 Feb 2015

UPDATE 2-CVS Health revenue beats as pharmacy services sales rise

Feb 10 - CVS Health Corp reported a better-than-expected quarterly net revenue, boosted by growth in its Medicaid business and strength in specialty drug sales.

10 Feb 2015

CVS Health revenue rises nearly 13 pct

Feb 10 - CVS Health Corp, the No. 2 U.S. drugstore operator, reported a near 13 percent rise in quarterly net revenue, helped by an increase in pharmacy same-store sales.

10 Feb 2015

AbbVie expects more than $3 billion in annual hepatitis C drug sales

- AbbVie Inc's chief executive said on Friday the company's new hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences .

30 Jan 2015

Competitors

  Price Chg
Catamaran Corp (USA) (CTRX.OQ) $59.56 +0.05
UnitedHealth Group Inc. (UNH.N) $118.69 +0.43
CIGNA Corporation (CI.N) $130.66 +0.09

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks